ADXS-NEO is bioengineered to secrete an antigen-adjuvant fusion protein. ADXS-NEO is effective at generating T cells that target multiple neoantigens and antigen spreading/secondary epitope pools, at doses.

Subject 2 (CRC) experienced Grade 3 hypoxia and Grade 3 hypotension hours post dose. Subject 1 (NSCLC) experienced Grade 3 hypoxia after receiving the second dose.

CXCL-10 (pg/ml)
- Serum levels of IL-6 (pg/mL) hours post dose.
- MSS hours post dose.

Adverse events in subjects 1 and 2 are considered to be the result of increased toxicities in tumor drivers, WAVE binding, in regard to normal, and similarity to pathogens.

METHODS
- Exploratory Parts B and C: Subjects who received up to 3 prior lines of therapy, per the design, 2 planned dose levels)
- Safety
- Pt #3 Pt #2 Pt #1
- ADXS-NEO: SAFE, TOLERABLE, AND POTENTIALLY A BEST-IN-CLASS THERAPEUTIC.